Received Nov 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | UNK | — |
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | UNK | — |
suspected Vaccination failure; Shingles; lasting nerve damage; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (Verbatim: suspected Vaccination failure) (serious criteria GSK medically significant), shingles (Verbatim: Shingles) and nerve damage (Verbatim: lasting nerve damage). The outcome of the vaccination failure, shingles and nerve damage were not reported. It was unknown if the reporter considered the vaccination failure, shingles and nerve damage to be related to Shingles vaccine and Shingles vaccine. The company considered the vaccination failure to be unrelated to Shingles vaccine and Shingles vaccine. It was unknown if the company considered the shingles and nerve damage to be related to Shingles vaccine and Shingles vaccine. Additional Information: GSK receipt date 30 OCT 2025: This case was reported by a consumer via interactive digital media. The patient got both shots and still got shingles and had lasting nerve damage. The batch number was not provided and we and unable to contact the reporter. This case was considered as suspected vaccination failure since details regarding time to onset and laboratory confirmation shingles not reported.; Sender's Comments: A case of Vaccination failure, an unknown time after receiving 1st and 2nd dose of Shingles vaccine, in a patient. Based on the available information a?possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.